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Background: Tissue imaging of treatment-induced metabolic changes is useful for optimizing cancer therapies, but
commonly used methods require trade-offs between assay sensitivity and spatial resolution. Nanostructure-Initiator
Mass Spectrometry imaging (NIMS) permits quantitative co-localization of drugs and treatment response biomarkers
in cells and tissues with relatively high resolution. The present feasibility studies use NIMS to monitor
phosphorylation of 30-deoxy-30-fluorothymidine (FLT) to FLT-MP in lymphoma cells and solid tumors as an indicator
of drug exposure and pharmacodynamic responses.
Methods: NIMS analytical sensitivity and spatial resolution were examined in cultured Burkitt’s lymphoma cells
treated briefly with Rapamycin or FLT. Sample aliquots were dispersed on NIMS surfaces for single cell imaging and
metabolic profiling, or extracted in parallel for LC-MS/MS analysis. Docetaxel-induced changes in FLT metabolism
were also monitored in tissues and tissue extracts from mice bearing drug-sensitive tumor xenografts. To correct for
variations in FLT disposition, the ratio of FLT-MP to FLT was used as a measure of TK1 thymidine kinase activity in
NIMS images. TK1 and tumor-specific luciferase were measured in adjacent tissue sections using
immuno-fluorescence microscopy.
Results: NIMS and LC-MS/MS yielded consistent results. FLT, FLT-MP, and Rapamycin were readily detected at the
single cell level using NIMS. Rapid changes in endogenous metabolism were detected in drug-treated cells, and
rapid accumulation of FLT-MP was seen in most, but not all imaged cells. FLT-MP accumulation in xenograft tumors
was shown to be sensitive to Docetaxel treatment, and TK1 immunoreactivity co-localized with tumor-specific
antigens in xenograft tumors, supporting a role for xenograft-derived TK1 activity in tumor FLT metabolism.
Conclusions: NIMS is suitable for monitoring drug exposure and metabolite biotransformation with essentially
single cell resolution, and provides new spatial and functional dimensions to studies of cancer metabolism without
the need for radiotracers or tissue extraction. These findings should prove useful for in vitro and pre-clinical studies
of cancer metabolism, and aid the optimization of metabolism-based cancer therapies and diagnostics.
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Genetic and environmental cues, including stresses from
anti-cancer treatments, can induce significant changes in
cell and tissue metabolism. Understanding the relation-
ships between drug exposure and tissue metabolism can
improve diagnosis and treatment outcomes, and speed the
identification of new drug targets and biomarkers [1].
Quantification of coincident biotransformation of xeno-
biotics and endogenous metabolites in tumor tissues is
critical for understanding exposure-response relationships,
but currently demands an impractical degree of analytical
sensitivity and spatial resolution. Liquid chromatography-
tandem mass spectrometry (LC-MS/MS) characterization
of endogenous and xenobiotic metabolites is a cornerstone
of drug development, but most methods involve sample
extractions that sacrifice spatial resolution for analytical
sensitivity. Nanostructure-initiator mass spectrometry im-
aging (NIMS) is an extension of LC-MS/MS methods that
provides mass spectral as well as spatial information from
tissue samples.
Thymidine kinase (TK1) activity is an effective and
well-established model for monitoring cancer cell cycle
status and proliferation potential. This model is ideal for
testing the robustness of LC-MS/MS and NIMS analysis
for these types of studies as selective metabolite precur-
sors can be assessed, an expansion from early successes
using radiotracers to monitor specific metabolites [2].
TK1 activity is tightly linked to both proliferation status
and the tumor avidity of thymidine analog tracers [3-8].
It is expressed almost exclusively in the G1-S phase of
the cell cycle and is significantly elevated in proliferating
cells compared to resting or dying cells. TK1 activity can
be monitored via cellular retention of phosphorylated
thymidine or TK1-selective analogs such as 5-bromo-20-
deoxyuridine (BrdU) and 30-deoxy-30-fluorothymidine
(FLT) [5]. FLT is taken up by cells and phosphorylated to
30-deoxy-30-fluorothymidine monophosphate (FLT-MP) by
TK1. FLT is readily transported out of cells, but FLT-MP
is highly retained, and its accumulation can serve as
an indirect indicator of proliferating tumor mass. Im-
portantly, TK1 activity and FLT retention are dramatic-
ally reduced after efficacious treatment with anti-
proliferative drugs [9,10]. Recent reports suggest that
mass spectrometry quantification of FLT metabolism
to FLT-MP is useful for monitoring the disposition of
tumor imaging agents in studies of cellular prolifera-
tion without the need for radioactivity, which is
required for positron emission tomography (PET) stud-
ies with [18F]-FLT [11,12].
The potential utility of LC-MS/MS and NIMS as ana-
lytical tools in these types of experiments has been indi-
cated by the recent advancements in mass-based
metabolite profiling. These advancements have allowed
for the analysis of relatively small samples without theneed for radiotracers, permitting untargeted analyses of
tumor drug responses [1]. In a recent example, the im-
munosuppressant drug rapamycin was shown to rapidly
induce pronounced changes in endogenous metabolism
in lymphoid cells by LC-MS/MS [13]. Still, sample prep-
aration for such methods requires tissue extraction, sac-
rificing anatomical resolution for analytical sensitivity
[14,15], highlighting the need for improved metabolo-
mics methodologies. Advancements in mass spectrom-
etry imaging (MSI) and profiling provide promising new
tools for metabolomics studies. Some methods are label-
free and generate accurate mass measurements across a
broad range of analytes. This allows for information-rich,
high-specificity biochemical analyses of tissues [16], cells
[17,18], and enzyme activity [19].
NIMS is one such improved metabolomics method-
ology and is a desorption/ionization MSI method that
can be used for the analysis of metabolites in single cells
and tissues without the need for matrix [20,21]. Thus,
sample preparation for NIMS imaging is straightforward,
rapid, preserves tissue integrity, and maintains metabol-
ite spatial distribution during image acquisition. These
features permit the characterization of dynamic cell and
tissue metabolic responses to pharmacological inter-
ventions [22]. NIMS thus allows higher resolution quan-
tification of analytes than radiometric imaging and
micro-dissection/extraction methods, adding a new di-
mension for tracking both substrates and metabolic
products [19-21]. NIMS can also be used to measure
metabolites in single cells [15], raising the possibility that
this method might be useful for characterizing tumor drug
responses with high resolution.
To explore the utility of NIMS technology for
exposure-response studies in cancer drug development,
changes in endogenous and xenobiotic metabolism were
monitored at the single cell level and in tumor tissues
using the TK1 activity model as a proof of principle. LC-
MS/MS and NIMS methods were also compared to
examine lymphoma and solid tumor anti-proliferative
chemotherapy. The results presented here demonstrate
that NIMS provides sufficient analytical sensitivity and
spatial resolution to detect relevant pharmacodynamic
responses in pre-clinical models, and demonstrate the
potential of mass-based approaches for optimizing can-
cer diagnostics and tumor imaging.
Materials and methods
Cell culture and drug treatments
Raji Burkitt’s lymphoma cells (CCL-86; ATCC, Manassas,
VA, USA) were propagated as per supplier recommenda-
tions, in complete growth medium consisting of RPMI-
1640 medium supplemented with 10% heat-inactivated
fetal bovine serum (FBS, Sigma, St. Louis, MO, USA), 100
IU/mL penicillin, 100 μg/ml streptomycin, and 2mM L-
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5% CO2 incubator. Cell cultures were maintained at a
density of no more than 350,000 cells/mL, and cultured for
no more than 30 total passages. Prior to treatment, cells
were washed free of complete growth medium and re-
suspended in minimum essential medium (MEM) (that is,
without FBS) to a density of approximately 100,000 cells/
mL. Drug-treated cell cultures were split into aliquots for
extraction and LC-MS/MS analysis, or for NIMS analysis
as described below. For studies of endogenous metabolite
responses to chemotherapy, Raji cells were treated with 50
μM rapamycin or 0.5% (v/v) dimethyl sulfoxide (DMSO) as
a vehicle control for up to 90 minutes at 37°C in a 5% CO2
incubator. Four experimental replicate samples were pre-
pared. For studies of xenobiotic metabolism, Raji cells were
treated with 0.5mM FLT or 0.5% distilled water vehicle
control at 37°C in a 5% CO2 incubator for 60 minutes.
Two experimental replicate samples were prepared, and
two technical replicate spots from each of these independ-
ent samples were deposited on the NIMS surface.
LC-MS/MS analysis and metabolite profiling of lymphoma
cell extracts
Drug- or vehicle-treated Raji cells were centrifuged at
400 × g for 1 minute and the supernatant was removed.
In order to remove confounding media components,
cells were washed three times in 1 mL ice cold
phosphate-buffered saline (PBS). After the third wash,
cells were suspended in 100 μL of extraction solvent
containing 10% chloroform, 40% methanol, and 50%
nanopure water, and centrifuged at 15,000 × g for 5 min-
utes. Thus clarified, the supernatant was collected and
stored at −80°C for subsequent LC-MS/MS analysis. All
Raji cell LC-MS/MS analyses were performed on an Agi-
lent 1200 series high-performance liquid chromato-
graphy (HPLC) system coupled to an Agilent 6538
Q-TOF mass spectrometer (Agilent Technologies, Santa
Clara, CA, USA) operated in positive electrospray
ionization mode. A 4-μL injection volume of rapamycin-
or vehicle-treated Raji cell extracts was used. Compara-
tive analysis of rapamycin- and vehicle-treated LC/MS
data was performed with XCMS [23] to identify
rapamycin-sensitive metabolites, a subset of which were
further analyzed by targeted LC-MS/MS using the same
HPLC conditions and Q-TOF acquisition parameters.
MS/MS spectra were compared to the METLIN metab-
olite database for metabolite identification [24].
Single cell NIMS imaging and metabolite profiling
NIMS substrates were prepared as described [25]. In
brief, p-type silicon wafers, 500 to 550 μm thick with
0.01 to 0.02 Ω cm resistivity (Silicon Quest Inter-
national, Santa Clara, CA) were cut into 33 mm2 pieces.
The wafers were soaked in Piranha solution (sulfuricacid and hydrogen peroxide (2:1)) overnight, washed
thoroughly with nanopure water and then dried using
nitrogen gas. Etching was carried out by clamping the
wafer in a Teflon chamber. Gold foil was used for the
anode and a platinum loop as the cathode; a 25% etha-
nolic hydrogen fluoride solution was then added to the
chamber. A BIO-RAD PowerPack1000 (Hercules, CA,
USA) was connected and run at a constant-current
mode (300 mA) for 30 minutes. The etched wafers were
washed in methanol and evaporated to dryness using ni-
trogen gas. Bis(heptadecafluoro-1,1,2,2-tetrahydrodecyl)
tetramethyldisiloxane (Gelest, Morrisvilles, PA, USA)
(100 μL) was applied to the surface of the chip and
allowed to sit at room temperature for 1 h before using
nitrogen gas to remove excess from the surface. The
drug- or vehicle-treated Raji cells were washed and cen-
trifuged as described above, and the supernatant was
carefully removed. Cell pellets were immediately re-
suspended to a density of 5 to 10 cells/μL in cold PBS
by gentle pipetting. Thus diluted, cell suspensions were
immediately applied to the NIMS surface in 10-μL
aliquots and immediately transferred to a desiccated,
room temperature vacuum. Sample spots were visibly
dry within one minute. NIMS imaging data was acquired
at 5-μm intervals using an AB/SCIEX 5800 mass spec-
trometer in negative-mode. NIMS images of isolated
cells were generated using an FLT-MP/FLT intensity
ratio, which was calculated for each pixel to generate a
ratiometric image. Individual FLT-MP and FLT inten-
sities were calculated as an integrated peak area within a
100-ppm window centered on the calibrated FLT-MP or
FLT peak, using Matlab (Version 2010b, The Mathworks
Inc., Natick, MA, USA). Single-cell mass spectra and 2-
dimensional ratiometric images with four-fold nearest
neighbor interpolation were generated with Matlab and 3-
dimensional images were generated with Fiji (http://fiji.sc/).
Median normalized total-ion intensity images were gener-
ated with Biomap (http://www.maldi-msi.org/).
Mouse solid tumor xenograft models, drug treatments,
and tissue preparation
All animal experimental procedures complied with the
Guide for the Care and Use of Laboratory Animals (In-
stitute for Laboratory Animal Research, 1996) and were
approved by the Pfizer Worldwide Research and Devel-
opment Institutional Animal Care and Use Committee.
LC-MS/MS studies of FLT metabolism in tumor tissues
were performed using a HCT116 colorectal carcinoma
xenograft model. 2.5 million HCT116 cells (CCL247;
ATCC) were implanted in the dorsal region of five fe-
male Nu/Nu mice (Charles River Breeding Laboratories,
Boston, MA, USA) per treatment group. When tumors
reached 100 to 120 mm3 in volume, typically eight days
after implantation, animals received an intra-peritoneal
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after docetaxel treatment, each animal received an intra-
peritoneal injection of non-radioactive FLT (2μg/kg;
approximately 0.2 nanomoles). Two hours later, the ani-
mals were euthanized, and tissues were excised then im-
mediately frozen in liquid nitrogen until extraction and
LC-MS/MS analysis (see below).
NIMS tissue imaging and immunofluorescence micros-
copy were performed on tissues excised from SCID-beige
mice bearing MDA-MB-231Luc breast tumor xenografts.
Two million MDA-MB-231Luc cells (Xenogen Corp.,
Alameda, CA, USA) were implanted in the dorsal region of
female SCID-beige mice (Charles River Labs). When
tumors were in the range of 200 to 600 mm3, two mice (per
group) received an intra-peritoneal injection of 15 mg/kg
docetaxel or vehicle 22 hours prior to intra-peritoneal ad-
ministration of non-radioactive FLT (210 μg/kg; approxi-
mately 22 nanomoles).
LC-MS/MS quantification of FLT and FLT-MP from
xenograft tumors and liver tissues
HCT116 xenograft tumors and liver samples were
excised and homogenized in methanol at a 3:1 ratio (v/w)
using a Mini BeadBeater (BioSPEC Bartlesville, OK,
USA). Analytes were extracted from the sample matrix
via protein precipitation, through the addition of 250 μL
of methanol containing internal standards to 100 μL of
reference standard samples, quality control samples, and
tissue homogenates [11]. After 15 minutes of centrifuga-
tion at 3200 × g and 4°C, the supernatant was transferred
to a 1-mL 96-well injection plate, dried under nitrogen at
ambient temperature, and reconstituted with 50 μL of in-
jection solvent composed of 0.5mM ethylenediaminete-
traacetic acid, and 1 mM citric acid. Chromatographic
separation was carried out on a reverse phase analytical
column (Phenomenex AQ C18, 100 × 2 mm, 5 μm)
coupled with Shimadzu LC-20AC pumps and a SIL-
20AC auto-sampler. The mobile phase consisted of solv-
ent A (0.1% formic acid) and solvent B (acetonitrile/0.1%
formic acid) at a flow rate of 0.2 mL/minute. A linear gra-
dient of 5 to 30% solvent B was applied during the first 3
minutes. Within 1 minute, solvent B was increased to
70% and held for an additional 0.5 minutes. At the end of
the run, solvent B was decreased to 5% in 0.2 minutes,
and held at 5% for 2.3 minutes for column re-equilibra-
tion. Analytes were then detected on a triple quadrupole
mass spectrometer (API4000, Applied Biosystems, Foster
City, CA, USA) by monitoring their specific precursor
and respective product ions in positive electrospray
ionization mode. The mass transitions for FLT, FLT-MP
and their correspondent internal standard d3-FLT and d3-
(FLT-MP) were 245.1 → 127.1, 325.3 → 81.2, 248 →
130.2, and 328.2→ 81.2 respectively. For HCT-116 xeno-
graft tumor extracts, FLT-MP peak areas and FLT mass(ng/g tissue) were quantified using d3-FLT as an internal
standard.
NIMS xenograft tumor activity imaging
Two hours after FLT administration, MDA-MB-231Luc
tumor-bearing animals were sacrificed for tumor har-
vest, and tumors were frozen in optimum cutting
temperature medium (OCT; Sakura Finetek, Torrance,
CA, USA) for cryo-sectioning. Frozen OCT-embedded
tumors were sliced into 4-μm sections with a cryostat
(Leica Microsystems, Buffalo Grove, IL, USA), placed on
the NIMS substrate, and immediately dried in a desic-
cated, room-temperature vacuum chamber. Adjacent
tumor sections were collected and placed on glass tissue
fixation slides for immunofluorescence microscopy and
H&E staining. NIMS imaging data was acquired at
50-μm spatial resolution with an AB/SCIEX 5800 mass
spectrometer (Applied Biosystems) in negative-mode
across the entire tumor area. Tumor sections from
docetaxel-treated and control mice were placed on a sin-
gle NIMS substrate. A second NIMS chip was used to
image tumor sections from the second set of docetaxel-
treated and control mice. From the NIMS imaging data,
an FLT-MP/FLT ratiometric image was calculated in an
identical manner as was done for FLT treated single-cell
analysis. In addition, median normalized total-ion inten-
sity, FLT extracted-ion intensity, and FLT-MP extracted-
ion intensity images with 4-fold nearest neighbor
interpolation were generated in Matlab.
Optical imaging of xenograft tumors
Double indirect immunofluorescent staining was per-
formed on OCT-embedded, cryostat sections of MDA-
MB-231Luc tumor samples. Sections were air-dried,
then baked at 37°C for 5 minutes. Sections were fixed in
10% neutral buffered formalin for 10 minutes. Following
fixation, sections were washed in 10X Bonds Wash Solu-
tion (Leica Microsystems, AR9590) for 5 minutes then
blocked in 10% Normal Donkey Serum (#017-000-121,
Jackson Immunoresearch, West Grove, PA, USA) for
30 minutes at room temperature. The primary antibo-
dies; anti-Luciferase (#G745A, Promega, Madison, WI,
USA, dilution 1:200) and anti-TK1 (ab76495, Abcam,
Cambridge, MA, USA, dilution 1:100), were applied to
the tissue sections and incubated overnight at 4°C. Sec-
tions were washed in Bonds Wash Solution followed by
the application of the fluorescent conjugate secondary
antibodies applied for 1 h: Alexa Fluor 594 donkey anti
rabbit (#A21207, Invitrogen, Carlsbad, CA, USA) and
Alexa Fluor 488 donkey anti goat (Invitrogen, #A11055).
DAPI (406- Diamidino-2-phenylindole dihydrochloride,
Sigma #32670-5MG-F) was applied for 5 minutes at
a dilution of 1:5000 from a working concentration of
5mg/mL as a nuclear counter stain. Slides were overlaid
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Dako, Carpinteria, CA, USA) for imaging. All immuno-
fluorescent images were generated using the Vectra™, a
multispectral microscope slide analysis system (Perkin-
Elmer, Waltham, MA, USA), equipped with epi-illumin-
ation, a Nuance™ camera, and appropriate filters. Filter
cubes used included: (1) UV excitation; 350 nm+/− 25 nm
420 nm long pass emission; (2) blue excitation; 470 nm
+/− 20 nm 515 nm long pass emission; (3) green excita-
tion; 535 nm +/− 20 nm 610 nm long pass emission.
Results and discussion
The present studies were pursued to test the suitability of
NIMS for imaging pharmacodynamic changes in tumor
metabolism. To demonstrate the selectivity and spatial
resolution of the method, NIMS was used to quantify
changes in specific endogenous and xenobiotic metabolites
single lymphoma cells, first by examining FLT metabolism
to FLT-MP, then by monitoring cellular responses to rapa-
mycin. Subsequent studies examined FLT metabolism in
solid tumors. In cells and tumors, results obtained using
NIMS were comparable with those from LC-MS/MS ana-
lysis of cell and tissue extracts. In solid tumors, FLT-MP
distribution co-localized with TK1 and tumor-specific anti-
gens, providing additional evidence that cancer cells are the
predominant site of FLT metabolism in these tumors. The
utility of NIMS for simultaneously characterizing exposure
to drugs and tracers should facilitate the optimization of
in vitro proliferation assays and (18F)-FLT PET tumor im-
aging, which in turn should aid the identification of com-
plementary measures of tumor drug responses.
Mass spectrometry imaging of metabolism in single cells
TK1-mediated metabolism was chosen as a model sys-
tem for monitoring drug exposure and pharmacody-
namic responses. Some of the most commonly used cell
proliferation assays measure cellular retention of thymi-
dine or TK1-selective analogs, such as (3H)-Thymidine,
BrdU, and (18F)-FLT. The cellular retention of these en-
tities correlates with intracellular TK1 expression [26].
TK1 is expressed almost exclusively in G1-S phase cells,
and treatment-induced changes in tracer retention are
often interpreted as alterations in cell cycle progression
or cell viability. However, most of these assays do not ac-
count for the behavior of the parent tracer, which varies
across cell lines and tissues due to cell culture condi-
tions, the actions of transporter inhibitors, and off-target
drug effects [27,28]. Our previous work using LC-MS/
MS clearly demonstrates that mass spectrometry can
quantitatively detect the conversion of tracer amounts of
FLT to FLT-MP [11]. We therefore used NIMS to meas-
ure FLT metabolism in single cells.
Raji Burkitt’s lymphoma cells are highly proliferative,
and thus express high endogenous levels of TK1 [29,30].Here, Raji cells were treated with 0.5 mM FLT or vehicle
for 60 minutes, after which FLT metabolism to FLT-MP
was analyzed using NIMS. This dose of FLT is well
above tracer concentrations and was selected to assure
sufficient conversion of FLT to FLT-MP for detection of
single cells using NIMS. FLT is an extremely potent
anti-retroviral drug that is relatively well tolerated by
cells and animals exposed to high doses over short peri-
ods of time [31,32]. Since FLT competes with endogen-
ous thymidine, it is expected to have direct effects on
thymidine metabolism. To demonstrate NIMS suitability
for monitoring more distal pharmacodynamic responses,
Raji cell responses to the starvation mimetic immuno-
suppressant drug, rapamycin, were also monitored using
NIMS. In both cases cells were pelleted by centrifuga-
tion, re-suspended in PBS to a density of approximately
5 to 10 cells/μL, then immediately applied to a NIMS
surface and dried under vacuum. This dilution proced-
ure reduces cellular aggregation on the NIMS surface
(our unpublished observations). The rapid drying
process and analysis under high vacuum helps to arrest
post-collection cellular metabolism, and the fluorinated
surface of NIMS chips limits the dispersal of metabolites
sufficiently to distinguish single cells from matrix con-
taminants [15]. In this study, due to the small cellular
diameter and relatively low number of cells on the NIMS
surface, NIMS spectra were generated using a 5-micron
step size, which also provides higher resolution of cellu-
lar geometry.
Mass spectrometry images of FLT-treated Raji cells
show numerous 10- to 15-micron regions with elevated
ion intensity (Figure 1A, left panel). The size and spec-
tral complexity of these features is consistent with the
presence of Raji cells on the chip surface. The total ion
intensity in these putative cells after treatment with FLT,
vehicle or 50 μM rapamycin can also be observed in
Figure S1 A, B, and C respectively, in Additional file 1.
In order to further distinguish individual cells amongst
higher intensity non-specific ions, NIMS images were
also generated for glucose and uridine. The signal inten-
sities for glucose (Figure 1A, middle panel) and uridine
(right panel), respectively, are in the same positions on
the 2-dimensional NIMS surface, outlining putative cells.
Figure S1 in Additional file 1 also shows that the con-
centrations of these endogenous metabolites did not
change after FLT or rapamycin treatment. Careful exam-
ination of these figures further shows that the most in-
tense spots in the total ion intensity images do not
necessarily overlap with uridine and glucose single ion
intensity images, highlighting the value of single ion im-
aging for discriminating specific metabolic features in in-
dividual cells and tissues. This co-localization of high
concentrations of water-soluble endogenous metabolites
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Figure 1 Single cell endogenous and xenobiotic metabolite detection using nanostructure-initiator mass spectrometry (NIMS). NIMS
total ion intensity (panel A, left), glucose ion intensity (center) and uridine ion intensity (right) of 30-deoxy-30-fluorothymidine (FLT)-treated Raji
cells. The total-ion NIMS image indicates that numerous cells are present in the same regions on the NIMS surface as suggested by high-intensity
localized signals. (B) Typical NIMS mass spectra observed from a pixel corresponding to a putative single cell in the NIMS Raji cell images. Left
panel, FLT peak [M-H] 243.08 m/z) from a single cell; center, FLT-MP [M-H]323.05 m/z) peak from a single cell; right, single-pixel NIMS spectrum
across the 75 to 650 m/z range.
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These figures also show that the cellular intensities of
metabolically distinct ions can vary enough that differ-
ences in signal threshold settings can lead to loss of sig-
nal from some cells. In FLT-treated samples, however,
the presence of FLT-MP reflects both thymidine kinase
activity and exposure to FLT. Mass spectra taken from
an individual pixel show both FLT (Figure 1B, left panel)
and FLT-MP (center panel) as well as the m/z range 75
to 650 (right panel). The breadth and complexity of
these mass spectra demonstrate the exquisite specificity
of mass-based analysis using NIMS and highlight the po-
tential value of simultaneous measurement of parent
drugs and their metabolites for identifying tissue struc-
tural features with cell-level resolution.
Although FLT cellular retention is primarily driven by
TK1 activity, TK1 substrate availability and the catabol-
ism of its reaction end products can affect FLTaccumulation [12,27,28,33,34]. We sought to correct for
these factors and potential spectrum-wide intensity vari-
ation that can result from localized inhomogeneity
within the sample on the NIMS surface. Specifically, we
monitored both FLT and FLT-MP in order to generate
ratiometric NIMS images of TK1 activity for each pixel.
In Figure 2, regions with high TK1 activity (that is,
regions with high FLT-MP/FLT ratios) in the FLT-
treated sample are associated with cells, a distribution
that likely reflects intracellular FLT biotransformation
mediated by TK1. The individual peaks shown in Figure 2
thus represent the 3-dimensional FLT-normalized FLT-MP
peak intensities from single cells. Most cells showed con-
siderable accumulation of FLT-MP relative to FLT. This
rapid conversion of FLT to FLT-MP reflects significant
competition with endogenous thymidine and suggests that
the high dose of FLT used in these NIMS studies might
have pharmacological effects. Indeed, examination of NIMS
Figure 2 Nanostructure-initiator mass spectrometry (NIMS) single-cell FLT-MP/FLT ratiometric imaging. Ratiometric analysis indicates no
FLT-MP/FLT intensity in untreated Raji Cells (top right), and significant FLT-MP metabolite production and retention in FLT-treated Raji Cells (bottom).
Cells were plated sparsely to ensure that single cells were imaged. FLT, 30-deoxy-30-fluorothymidine; FLT-MP, 30-Deoxy-30-Fluorothymidine
monophosphate.
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dysregulations in thymidine metabolism after only brief
high dose FLT treatments (data not shown). Therefore, in
order to demonstrate the suitability of NIMS for measuring
downstream pharmacodynamic responses, Raji cells were
treated with rapamycin, a potent immunosuppressant and
starvation mimetic that causes rapid dysregulations in cel-
lular metabolism [13]. Raji cell cultures were exposed
to 50 μM rapamycin or vehicle for up to 90 minutes and
then split into aliquots for analysis by NIMS single-cell im-
aging or LC-MS/MS. Rapamycin was readily detectable by
NIMS, and cellular concentrations of rapamycin increased
across the entire 90-minute time course (Figure 3). Con-
sistent with the results of Ramanathan and Schreiber [13],
NIMS metabolite profiling of 60-minute samples showed
significant dysregulation of an array of endogenous meta-
bolites, including several with identifiable MS/MS frag-
mentation patterns that were confirmed using LC-MS/MS
(Table 1). This finding demonstrates that NIMS has ad-
equate sensitivity to detect both drugs and endogenous
biomarkers at the single cell level. Taken together, these
results confirm that NIMS provides a highly accurate
method for measuring the cellular conversion of specific
metabolites, providing a new dimension for analyzing cell
metabolism and tumor drug responses.
LC-MS/MS quantification of solid tumor FLT metabolism
Tumor imaging using (18F)-FLT PET is an established
method for linking tumor responses to anatomy, andprovides a powerful tool for drug discovery [5]. However,
this method requires a radioactive label for detection,
and cannot discriminate between the parent tracer and
its metabolites. Mass spectrometry quantification of FLT
metabolism to FLT-MP by NIMS eliminates the need for
radioactivity and can also provide useful information on
the spatial localization and disposition of tracers, drugs,
and other metabolites. To demonstrate that mass spec-
trometric monitoring of TK1 activity is suitable for
studying pharmacodynamic responses in xenograft
tumors, nude mice implanted with HCT116 colorectal
carcinoma cells were treated with 30 mg/kg docetaxel
for 22 or 46 h, then given a tracer dose of non-
radioactive FLT. After 2 h, the animals were sacrificed
and tumors were excised along with livers, which served
as a non-proliferative tissue control. Tumor extract FLT
and FLT-MP were analyzed by LC-MS/MS using the
methods of Li et al. [11]. As shown in Figure 4A, FLT
distributed equally well into tumor and liver tissues re-
gardless of treatment group. FLT-MP accumulation
was also readily detected in tumor tissues (panel B), but
FLT-MP was below the assay limit of detection in liver.
Furthermore, FLT-MP accumulation was significantly
higher in tumors from vehicle-treated animals when
compared to samples collected 24 and 48 hours after
docetaxel treatment; a result that is consistent with the
well characterized anti-proliferative effects of this drug
[35]. Thymidine and its phosphorylated metabolite thy-
midine monophosphate (TMP) were detectable in both
Figure 3 Nanostructure-initiator mass spectrometry (NIMS) detection of rapamycin pharmacokinetics in Raji cells. Ninety-minute
treatment shows increased drug uptake over time.
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predominant thymidine kinase in quiescent and dying
cells [36]. Taken together, these data show that mass
spectrometry is suitable for measuring changes in en-
dogenous and xenobiotic metabolism (that is, the con-
version of thymidine to TMP and FLT to FLT-MP) as an
indicator of solid tumor drug responses. While these
studies were underway, Zhang and colleagues described
a comparison of (18F)-FLT PET imaging of xenograft
tumors with LC-MS/MS measurement of FLT metabol-
ism [12]. That study demonstrated a direct correlation
between (18F)-FLT tracer avidity and tumor accumula-
tion of non-radioactive FLT-MP, and revealed that
MDA-MB-231Luc breast tumor xenografts had more fa-
vorable growth characteristics and FLT tracer avidity
than HCT116 xenografts. Those findings led us to use
the MDA-MB-231Luc model for the NIMS studies
described below.Table 1 Selected rapamycin-sensitive metabolites
identified by nanostructure-initiator mass spectrometry
(NIMS)
Metabolite Metabolite median fold change P-value
Tigylglycine 3.4 0.0112
N-acetyl-glutamic acid 10 0.0331
Uridine monophosphate 2.0 0.0021
Isobutyrylcarnitine 2.3 0.0368
Stearic acid 4.7 0.0893
D-glucose 2.3 0.0713
Raji cells were treated with Rapamycin or vehicle for 60 minutes as described
in Materials and Methods, then divided into matching aliquots for NIMS
analysis. Metabolites with unambiguous MS/MS fragmentation patterns that
represent disparate metabolic pathways were also quantified and compared to
reference standards via LC-MS/MS, and are shown here.NIMS quantification of solid tumor FLT metabolism
MDA-MB-231Luc tumor-bearing mice were treated with
vehicle or an efficacious dose of docetaxel for 22 h, and
then given an intra-peritoneal injection of non-
radioactive FLT. The dose used in these proof-of-
principle studies is approximately 100 times that used in
the HCT-116 experiments described above, and was
chosen to assure that FLT would be detectable in at least
some tumor regions without undue toxicity. Two hours
after FLT treatment, tumors were harvested, embedded
in OCT medium and frozen. Four-micron sections were
cut from the harvested tumors, placed on the NIMS sur-
face, and immediately dried under vacuum. NIMS im-
aging of tumor sections was performed with 50 μm
spatial resolution and FLT-MP/FLT ratiometric images
were generated (Figure 5 and Additional file 2). This
step size was chosen to facilitate speed of analysis. Dif-
ferences in total ion scans indicate metabolic inhomo-
geneity within each tissue slice, but these differences are
confined to specific areas and separated by distances on
a scale of several hundred microns, which is resolvable
by the 50-μm step size used for NIMS imaging. Varia-
tions in the FLT-MP/FLT ratio across the tissue were
likely minimized because ratiometric images suggest
general metabolic homogeneity across the tissue. Con-
sistent with docetaxel pharmacology, total ion intensity
NIMS images and FLT-MP ratiometric NIMS images
from vehicle- (Additional file 2: Figure S2A and C) and
docetaxel-treated tumors (Additional file 2: Figure S2B
and D) clearly distinguish aggressively growing vehicle-
treated tumors from docetaxel-treated tumors. Reduced
FLT-MP in docetaxel-treated mice is also apparent from
FLT-MP extracted ion intensity images, whereas limited



































































Figure 4 Liquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of 30-deoxy-30-fluorothymidine (FLT) and 30-deoxy-30-
fluorothymidine monophosphate (FLT-MP) accumulation in xenograft tumors and liver extracts from HCT116 tumor-bearing mice. FLT
is distributed equally well in tumors and non-proliferative liver control tissues from all treatment groups (ng FLT/g tissue, panel A). FLT-MP is
detectable in tumor tissues, but not in liver controls (panel B, FLT-MP peak area). Compared to vehicle-treated tumors (gray bars, n = 5) FLT-MP is
significantly reduced 24 h (white bars; n = 4; P = 0.009, Student’s t-test) and 48 h (hashed bars, n = 4; P = 0.165) after docetaxel treatment. FLT-
MP concentrations were below the validated lower limit of quantitation of the assay in matched liver extracts (dotted lines) from all treatment
groups. Thymidine and thymidine monophosphate (TMP) were detectable in all tissues (panels C and D). Results represent means +/− SD for
each treatment group.
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In situ MS/MS fragmentation data was also collected to
verify NIMS accurate mass measurements against a pure
FLT-MP reference standard applied to the same NIMS
surface just outside the tumor edge. The NIMS MS/MS
spectrum obtained from tumor sections matches the
fragmentation pattern observed from pure FLT-MP
standard (Figure 6). Taken together, these NIMS tissue
imaging results are consistent with the LC-MS/MS
results described above for HCT116 xenografts as well
as previous reports examining (18F)-FLT metabolism the
MDA-MB-231Luc model [12]. In all cases, FLT-MP is
more abundant in vehicle-treated xenograft tumors
compared to docetaxel-treated tumors.
TK1 and tumor antigen distribution in xenograft tumors
The distribution of TK1 protein and tumor cell line-
specific luciferase was examined using immunofluores-
cence microscopy (IFM) of adjacent tissue sections from
vehicle-treated mice (Additional file 3). In these samples,
TK1 immunoreactivity can arise from proliferating mur-
ine cells or xenograft tissues, while luciferase is
expressed solely in xenograft tumor cells. H&E staining
showed that homogenously distributed tumor cells makeup the majority of vehicle-treated xenograft tumors, and
that docetaxel treatment caused widespread necrosis in
treated tumors (data not shown). IFM of vehicle-treated
tumors shows widespread luciferase immunoreactivity
indicative of xenograft cells. Luciferase consistently co-
localizes with both nuclear DAPI staining and TK1
immunoreactivity, indicating that most of the tumor
mass consists of proliferating, xenografted cells. Despite
the absence of a direct comparator, TK1 and tumor cell
line-specific luciferase were co-localized in control
tumors in a pattern similar to that of the highest FLT-
MP/FLT ratios, further implicating tumor-derived TK1
in the metabolism of FLT to FLT-MP.
Study limitations
In our NIMS lymphocyte experiments, we describe
metabolite-rich regions as putative cells, but it is pos-
sible that FLT might leak from cells during desiccation
on the NIMS surface, leading to artifactual accumulation
of metabolites in cell-sized spots. The abundance and
consistent co-localization of multiple highly water-
soluble analytes across cell populations in different treat-
ment groups argues against this and suggests that if
there is leakage of metabolites from the cells, it is
Figure 5 Nanostructure-initiator mass spectrometry (NIMS) FLT-MP/FLT ratiometric imaging of docetaxel- and vehicle-treated breast
tumor mouse xenografts. Three-dimensional NIMS images of tumor sections from 30-deoxy-30-fluorothymidine (FLT)-treated mice shows
significantly higher conversion of FLT to FLT-MP in vehicle-treated (left) versus docetaxel-treated mice (right). Tumor sections from one set of
vehicle- and docetaxel-treated mice were placed in close proximity on a single NIMS chip and imaged using NIMS (Chip #1, top). As further
validation, tumor sections from a second set of vehicle- and docetaxel-treated mice were placed in close proximity on a second NIMS chip and
imaged using NIMS (Chip #2, bottom). A total of four independent tumors were imaged, two from docetaxel-treated and two from vehicle-
treated mice. FLT-MP/FLT ratios were normalized to a maximum value of 1 for each NIMS chip.
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dilution, and plating protocols described here likely re-
duce contamination from media components, including
metabolites released from cells during sample prepar-
ation [15].
The pharmacology of high dose FLT may also con-
found our Raji cell FLT studies, and may limit the useful-
ness of these feasibility studies for optimizing (18F)-FLT
PET methods. Published reports describe the toxicity of
azidothymidine (AZT), FLT, and other anti-retroviral
drugs in cell lines and mice [31,32]. Those studies show
that FLT is generally well-tolerated at lower doses, but
that cytotoxicity and bone marrow suppression are seen
at high, sustained FLT concentrations, likely due to
effects on DNA replication (3-day cytotoxicity IC50 =
240 μM) [31]. Given that, we chose to use this relatively
high FLT exposure with a shorter incubation time to en-
hance the likelihood that FLT-MP could be detected in
single cells.
Given the observed metabolic dysregulations induced in
Raji cells by FLT and rapamycin treatment, it is also im-
portant to consider the potential effects of temperature
shifts, centrifugation, osmotic and oncotic shifts, and
other experimental manipulations on cell biology. Our ex-
perimental designs and sample handling protocols for
both in vitro and in vivo studies attempted to minimizethe impact of sample handling on xenobiotic and en-
dogenous metabolism, but practical limitations of the
method no doubt introduce some degree of uncontrolled
variability into our results.
Our in vivo studies were designed to test the technical
feasibility of NIMS imaging for monitoring pharmacody-
namic responses to cancer chemotherapy. Although
NIMS clearly shows drug-induced changes in FLT me-
tabolism in docetaxel-treated mice, these studies were
not designed to address the selectivity and specificity of
these methods for TK1 activity, cell cycle status, nor the
mechanisms that drive the observed changes in FLT me-
tabolism. Instead, we relied on published reports and
our own experience to design dosing and sampling strat-
egies. Docetaxel elicits reproducible and predictable
changes in radiotracer, bioluminescence and immuno-
histochemical endpoints in MDA-MB-231luc xenograft
models [12,37-48]. TK1 expression and treatment-
induced changes in TK1 activity, reflected by (18F)-FLT
tracer, FLT tumor avidity and kinetics, are also quite pre-
dictable in the model systems used here. In both MDA-
MB-231 and Burkitt’s lymphoma xenografts it was
shown that FLT uptake two hours after injection (the
same time point used in our in vivo studies) varies by
less than 25% [47]. Considering these factors, we limited
the present feasibility study to two mice per treatment
Figure 6 Comparison of the nanostructure-initiator mass spectrometry (NIMS) tandem mass spectrometry (MS/MS) fragmentation
pattern of a 30-deoxy-30-fluorothymidine-monophosphate (FLT-MP) reference standard with that of putative FLT-MP from tumor
tissues. The FLT-MP fragmentation pattern [M-H] 323.05 m/z) acquired in situ from two separate tumor sections (panel A, two spectra overlay)
matches that of an FLT-MP reference standard spotted adjacent to the tumor edge on the same NIMS chip (panel B). The reference standard
fragmentation spectrum is displayed inverted to enable a more direct comparison of tumor-derived spectra with that of the reference standard.
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merous publications [2-6,8-10,27,29,49-61], suggest that
the sample sizes used for these studies are appropriate
for the current application.
With regard to the specificity of this approach for
measuring TK1 activity, extensive literature describes
the cell biology of TK1 and its critical role in the differ-
ential disposition of FLT and other thymidine analogs
[2-6,8-10,27,29,49-61]. Those reports and others indicate
that the drug-induced changes in FLT metabolism
reported here likely reflect alterations in intracellular
TK1 abundance, but this question was not directly
addressed. Manipulation of TK1 expression in isogenic
cells would provide an additional test of the linkage be-
tween TK1 expression and changes in the FLT-MP/FLT
ratio after drug treatment. Two recent publications
address this issue in relevant biological models. First,Barthel and colleagues [56] examined (18F)-FLT uptake
in vivo using L5178Y mouse lymphoma cells containing
the functional heterozygous TK1+/− allele and a corre-
sponding TK1−/− L5178Y variant derived from mutation
of the TK1 locus. The report demonstrated that TK1
protein expression drives (18F)-FLT uptake in lymphoma
cells. Secondly, Zhang and colleagues addressed the link-
age between TK1 expression and FLT tracer uptake in
drug-treated mice [12]. Mice bearing MDA-MB-231Luc
xenografts were treated with the cell cycle inhibitor drug
PD-0332991, which caused cell cycle arrest, a reduction
in BrdU incorporation, reduced Ki-67 and TK1 protein
expression, and lowered (18F)-FLT uptake in tumor tis-
sues. Drug washout led to a return to asynchronous
growth, return of proliferation antigens, and an increase
in (18F)-FLT uptake. Taken together, these reports fur-
ther support the assertion that the changes in FLT-MP/
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treatment-induced alterations in TK1 activity. It is im-
portant to note, however, that the NIMS approach
described here does not discriminate between TK1 loss
from dying cells (for example, via enzyme leakage) and
other modes of downregulation in cycling, viable cells.
Although regions of necrosis were clearly seen in the
tumor sections from docetaxel-treated cells, it remains
possible that the observed reduction in TK1 activity
shown in these studies is not entirely due to cytotoxicity.
One long-term goal of these studies is to identify en-
dogenous metabolic markers for discriminating non-
proliferative but viable cells from dead and dying cells.
Our experiments with cultured Raji cells suggest that
NIMS imaging of water-soluble endogenous metabolites
like glucose and uridine might help to identify intact,
non-proliferating tumor cells. Given the pleiotropic cyto-
toxicity of docetaxel [62,63], reliable interpretation of
such data would require more careful monitoring of
tumor drug exposure than was pursued in the present
studies.Conclusions
The results described here demonstrate that NIMS can
be used to detect drug exposure (that is, intracellular up-
take of FLT and rapamycin), xenobiotic metabolism (FLT
conversion to FLT-MP), and downstream pharmacody-
namic responses at the level of single cells. NIMS should
prove useful for further characterizing these cellular
responses and additional dissection of this biology.
Given the single-cell sensitivity of NIMS demonstrated
here, ratiometric imaging should enhance investigations
of metabolic heterogeneity in cells coincident with other
metabolic profiles. This tool would thereby provide a
means to identify endogenous metabolites with differen-
tial sensitivity to chemotherapy, some of which might
serve as novel indicators of cellular proliferation. The
identification of endogenous metabolite fingerprints
associated with different tissues and cell fates would also
eliminate issues associated with non-tracer doses of FLT,
like those used in the present studies. Ratiometric meas-
urement of an administered compound and its corre-
sponding metabolite should be generally applicable to
MSI studies of xenobiotic biotransformation in animal
models, particularly in cases where metabolites are
retained to some extent in cells of interest [22]. This
would permit MSI signal normalization to endogenous
metabolites instead of xenobiotics, which would further
improve metabolomic characterization of treatment
responses. The single-cell sensitivity demonstrated here
should also improve proof-of-concept studies in cell cul-
ture prior to more expensive and time-consuming phar-
macodynamic studies in animals.The clinical utility of these methods remains to be
seen, since the present studies focused entirely on cul-
tured cells and excised tissues. The present studies dem-
onstrate that NIMS likely has adequate sensitivity and
resolution to analyze cells from the circulation and pa-
tient tissue biopsies. These methods may therefore have
immediate utility in studies of hematological malignan-
cies or studies of circulating tumor cells. Sampling via
fine needle biopsy, for example, may allow for serial
studies of FLT metabolism, particularly in lymphoma
and other liquid tumors. Finally, since alterations in
FLT metabolism can reflect cellular changes that dra-
matically affect the disposition and pharmacological
activity of therapeutic nucleoside analogs [64], the meth-
ods described here should also aid the optimization of
existing anti-cancer therapies.
Additional files
Additional file 1: Figure S1. Total ion, glucose ion, and uridine ion
intensity nanostructure-initiator mass spectrometry (NIMS) images of Raji
cells. (A) FLT-treated cells, (B) vehicle treated cells, and (C) rapamycin-
treated cells. Equally scaled total ion NIMS images indicate that
numerous cells are present in the same regions on the NIMS surface as
suggested by high-intensity localized signals. Note that the vehicle-
treated NIMS chip has 87% background intensity of the FLT-treated chip.
Additional file 2: Figure S2. Total ion nanostructure-initiator mass
spectrometry (NIMS), 30-deoxy-30-fluorothymidine (FLT) and 30-deoxy-30-
fluorothymidine monophosphate (FLT-MP) extracted ion NIMS, and FLT-
MP/FLT ratiometric NIMS tumor images. Tumor section images from the
four mice used in this study, two vehicle-treated mice and two
docetaxel-treated mice. Tumor sections from (A) vehicle-treated and (B)
docetaxel-treated mice imaged on a single NIMS chip. Tumor sections
from two additional (C) vehicle-treated and (D) docetaxel-treated mice
on a second NIMS chip. NIMS total-ion and extracted-ion images are
normalized and scaled for comparison within a particular column.
Columns (from left) show total ion Intensity, FLT [M-H] 243.08 m/z)
extracted ion intensity, FLT-MP [M-H] 323.05 m/z) extracted ion intensity,
and FLT-MP/FLT ratiometric magnitude.
Additional file 3: Figure S3. Immunofluorescence images of tumor
sections. Images of vehicle-treated samples were generated from 4-μm-
thick tumor tissue slices adjacent to the tumor sections used to acquire
the nanostructure-initiator mass spectrometry (NIMS) images.
Representative images at 20× magnification from vehicle-treated tumors
(top panel: NIMS Chip 1 vehicle tumor; bottom panel: NIMS Chip 2
vehicle tumor). Displayed areas were selected to be representative of
viable tumor regions based on DAPI staining (blue); in addition TK1 and
anti-luciferase immunoreactivity (red and green, respectively) are shown.
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